Derivatization and combination therapy of current COVID-19 therapeutic agents: a review of mechanistic pathways, adverse effects, and binding sites
S El Kantar, B Nehmeh, P Saad, G Mitri, C Estephan… - Drug Discovery …, 2020 - Elsevier
Highlights•We summarized the mechanisms of action of 11 repurposed drugs for COVID-19
treatment.•We reviewed clinical trials performed on drugs to treat COVID-19 patients.•We …
treatment.•We reviewed clinical trials performed on drugs to treat COVID-19 patients.•We …
Derivatization and combination therapy of current COVID-19 therapeutic agents: a review of mechanistic pathways, adverse effects, and binding sites
S El Kantar, B Nehmeh, P Saad, G Mitri… - 2020 - expeditiorepositorio.utadeo.edu.co
Current treatment of patients with coronavirus 2019 (COVID-19) involves repurposed drugs
that inhibit viral infection by either binding to their respective targets or via modulating …
that inhibit viral infection by either binding to their respective targets or via modulating …
[HTML][HTML] Derivatization and combination therapy of current COVID-19 therapeutic agents: a review of mechanistic pathways, adverse effects, and binding sites
S El Kantar, B Nehmeh, P Saad, G Mitri… - Drug Discovery …, 2020 - ncbi.nlm.nih.gov
Current treatment of patients with coronavirus 2019 (COVID-19) involves repurposed drugs
that inhibit viral infection by either binding to their respective targets or via modulating …
that inhibit viral infection by either binding to their respective targets or via modulating …
Derivatization and combination therapy of current COVID-19 therapeutic agents: a review of mechanistic pathways, adverse effects, and binding sites
S El Kantar, B Nehmeh, P Saad, G Mitri… - Drug discovery …, 2020 - pubmed.ncbi.nlm.nih.gov
Current treatment of patients with coronavirus 2019 (COVID-19) involves repurposed drugs
that inhibit viral infection by either binding to their respective targets or via modulating …
that inhibit viral infection by either binding to their respective targets or via modulating …
[PDF][PDF] Derivatization and combination therapy of current COVID-19 therapeutic agents: a review of mechanistic pathways, adverse effects, and binding sites
S El Kantar, B Nehmeh, P Saad, G Mitri… - Drug Discovery …, 2020 - academia.edu
Current treatment of patients with coronavirus 2019 (COVID-19) involves repurposed drugs
that inhibit viral infection by either binding to their respective targets or via modulating …
that inhibit viral infection by either binding to their respective targets or via modulating …
Derivatization and combination therapy of current COVID-19 therapeutic agents: a review of mechanistic pathways, adverse effects, and binding sites.
S El Kantar, B Nehmeh, P Saad, G Mitri… - Drug Discovery …, 2020 - europepmc.org
Current treatment of patients with coronavirus 2019 (COVID-19) involves repurposed drugs
that inhibit viral infection by either binding to their respective targets or via modulating …
that inhibit viral infection by either binding to their respective targets or via modulating …
Derivatization and combination therapy of current COVID-19 therapeutic agents: a review of mechanistic pathways, adverse effects, and binding sites
S El Kantar, B Nehmeh, P Saad, G Mitri… - Drug discovery …, 2020 - pubmed.ncbi.nlm.nih.gov
Current treatment of patients with coronavirus 2019 (COVID-19) involves repurposed drugs
that inhibit viral infection by either binding to their respective targets or via modulating …
that inhibit viral infection by either binding to their respective targets or via modulating …